Related Experiment Videos
Insights
Oral long-acting isoprenaline effectively managed chronic heart block in 42% of patients for over 18 months. Careful patient selection is key for this treatment in elderly populations.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Chronic heart block presents management challenges, particularly in elderly patients.
- Oral sympathomimetic drugs offer a potential therapeutic avenue.
Purpose of the Study:
- To evaluate the efficacy and long-term outcomes of oral long-acting isoprenaline in chronic heart block patients.
- To identify predictors of response to oral isoprenaline therapy.
Main Methods:
- A study involving 203 patients with chronic heart block treated with oral long-acting isoprenaline.
- Survival rates and response to therapy were monitored over time.
- Intravenous isoprenaline response and dysrhythmia type were assessed as predictive factors.
Main Results:
- 42% of patients achieved satisfactory management with oral isoprenaline for a mean of 18.2 months.
- One, two, and three-year survival rates were 76%, 64%, and 57% respectively.
- Patients requiring pacing had higher survival rates (83%, 72%, 60% at 1, 2, 3 years).
Conclusions:
- Oral long-acting isoprenaline is valuable for long-term management of carefully selected chronic heart block patients.
- Response to intravenous isoprenaline and dysrhythmia type are key indicators for treatment success.
- Patients with heart failure or angina do not benefit from sympathomimetic drugs.
Abstract:
A study of 203 patients with chronic heart block treated with oral long-acting isoprenaline showed that 85 (42%) were maintained satisfactorily on the drug for a mean period of 18.2 months. The survival rates at one, two, and three years were 76%, 64%, and 57% respectively. In 115 patients treatment by pacing became necessary to control symptoms, and in these patients the survival rates at one, two and three years were 83%, 72%, and 60%.The two most valuable guides to patients' response to oral isoprenaline are the response to a trial dose of intravenous isoprenaline and the type of dysrhythmia associated with their Adams-Stokes attacks. Patients with heart failure with slow ventricular rates and those with angina of effort do not respond to treatment with sympathomimetic drugs.The majority of patients with chronic heart block are elderly, and in view of the complexity of pacing systems, and the need for skilled supervision of paced patients, oral long-acting isoprenaline remains of value in the longterm management of chronic heart block, provided patients are carefully selected for this form of therapy.